APO RESEARCH · REPORT
Adrenoleukodystrophy Drugs
Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP).
Product & engineering
Understand the product.
Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP).
Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.
There is currently no satisfactory therapeutic treatment available. Current treatments are limited, namely: Dietary therapy, Gene therapy, Hormone replacement and stem cell transplantation. Hormone replacement is standard for ALD patients demonstrating adrenal insufficiency.
Selected research
Industry Research
Adrenoleukodystrophy Drugs Industry Research Report 2026
Market perspective
Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP).
Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.
There is currently no satisfactory therapeutic treatment available. Current treatments are limited, namely: Dietary therapy, Gene therapy, Hormone replacement and stem cell transplantation. Hormone replacement is standard for ALD patients demonstrating adrenal insufficiency.
Read the full market overview
By region, North America has the highest share of revenue, exceeding 60 percent in 2019.
Report Scope
This report quantifies the global Adrenoleukodystrophy Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Adrenoleukodystrophy Drugs Market by Company
Bluebird Bio Inc
NeuroVia, Inc.
Orpheris, Inc.
Minoryx
MedDay Pharmaceuticals
Adrenoleukodystrophy Drugs Segment by Type
Hormone Replacement
Transplant
Others
Adrenoleukodystrophy Drugs Segment by Application
Childhood Cerebral ALD
Adrenomyeloneuropathy (AMN)
Addison-only
Others
Adrenoleukodystrophy Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adrenoleukodystrophy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Adrenoleukodystrophy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adrenoleukodystrophy Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Adrenoleukodystrophy Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Adrenoleukodystrophy Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Adrenoleukodystrophy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Hormone Replacement
- Transplant
- Others
Applications
- Childhood Cerebral ALD
- Adrenomyeloneuropathy (AMN)
- Addison-only
- Others
Companies covered
- Bluebird Bio Inc
- NeuroVia, Inc.
- Orpheris, Inc.
- Minoryx
- MedDay Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Adrenoleukodystrophy Drugs Market Size (2021-2032)
- 2.2.2 Global Adrenoleukodystrophy Drugs Sales (2021-2032)
- 2.2.3 Global Adrenoleukodystrophy Drugs Market Average Price (2021-2032)
- 2.3 Adrenoleukodystrophy Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Hormone Replacement
- 2.3.3 Transplant
- 2.3.4 Others
- 2.4 Adrenoleukodystrophy Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Childhood Cerebral ALD
- 2.4.3 Adrenomyeloneuropathy (AMN)
- 2.4.4 Addison-only
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Adrenoleukodystrophy Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Adrenoleukodystrophy Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Adrenoleukodystrophy Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Adrenoleukodystrophy Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Adrenoleukodystrophy Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Adrenoleukodystrophy Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Adrenoleukodystrophy Drugs, Product Type & Application
- 3.8 Global Manufacturers of Adrenoleukodystrophy Drugs, Established Date
- 3.9 Global Adrenoleukodystrophy Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Bluebird Bio Inc
- 4.1.1 Bluebird Bio Inc Company Information
- 4.1.2 Bluebird Bio Inc Business Overview
- 4.1.3 Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Bluebird Bio Inc Adrenoleukodystrophy Drugs Product Portfolio
- 4.1.5 Bluebird Bio Inc Recent Developments
- 4.2 NeuroVia, Inc.
- 4.2.1 NeuroVia, Inc. Company Information
- 4.2.2 NeuroVia, Inc. Business Overview
- 4.2.3 NeuroVia, Inc. Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 NeuroVia, Inc. Adrenoleukodystrophy Drugs Product Portfolio
- 4.2.5 NeuroVia, Inc. Recent Developments
- 4.3 Orpheris, Inc.
- 4.3.1 Orpheris, Inc. Company Information
- 4.3.2 Orpheris, Inc. Business Overview
- 4.3.3 Orpheris, Inc. Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Orpheris, Inc. Adrenoleukodystrophy Drugs Product Portfolio
- 4.3.5 Orpheris, Inc. Recent Developments
- 4.4 Minoryx
- 4.4.1 Minoryx Company Information
- 4.4.2 Minoryx Business Overview
- 4.4.3 Minoryx Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Minoryx Adrenoleukodystrophy Drugs Product Portfolio
- 4.4.5 Minoryx Recent Developments
- 4.5 MedDay Pharmaceuticals
- 4.5.1 MedDay Pharmaceuticals Company Information
- 4.5.2 MedDay Pharmaceuticals Business Overview
- 4.5.3 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Product Portfolio
- 4.5.5 MedDay Pharmaceuticals Recent Developments
5 Global Adrenoleukodystrophy Drugs Market Scenario by Region
- 5.1 Global Adrenoleukodystrophy Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Adrenoleukodystrophy Drugs Sales by Region: 2021-2032
- 5.2.1 Global Adrenoleukodystrophy Drugs Sales by Region: 2021-2026
- 5.2.2 Global Adrenoleukodystrophy Drugs Sales by Region: 2027-2032
- 5.3 Global Adrenoleukodystrophy Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Adrenoleukodystrophy Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Adrenoleukodystrophy Drugs Revenue by Region: 2027-2032
- 5.4 North America Adrenoleukodystrophy Drugs Market Facts & Figures by Country
- 5.4.1 North America Adrenoleukodystrophy Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Adrenoleukodystrophy Drugs Sales by Country (2021-2032)
- 5.4.3 North America Adrenoleukodystrophy Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Adrenoleukodystrophy Drugs Market Facts & Figures by Country
- 5.5.1 Europe Adrenoleukodystrophy Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Adrenoleukodystrophy Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Adrenoleukodystrophy Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Adrenoleukodystrophy Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Adrenoleukodystrophy Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Adrenoleukodystrophy Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Adrenoleukodystrophy Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Adrenoleukodystrophy Drugs Market Facts & Figures by Country
- 5.7.1 South America Adrenoleukodystrophy Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Adrenoleukodystrophy Drugs Sales by Country (2021-2032)
- 5.7.3 South America Adrenoleukodystrophy Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Adrenoleukodystrophy Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Adrenoleukodystrophy Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Adrenoleukodystrophy Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Adrenoleukodystrophy Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Adrenoleukodystrophy Drugs Sales by Type (2021-2032)
- 6.1.1 Global Adrenoleukodystrophy Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Adrenoleukodystrophy Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Adrenoleukodystrophy Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Adrenoleukodystrophy Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Adrenoleukodystrophy Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Adrenoleukodystrophy Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Adrenoleukodystrophy Drugs Sales by Application (2021-2032)
- 7.1.1 Global Adrenoleukodystrophy Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Adrenoleukodystrophy Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Adrenoleukodystrophy Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Adrenoleukodystrophy Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Adrenoleukodystrophy Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Adrenoleukodystrophy Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Adrenoleukodystrophy Drugs Value Chain Analysis
- 8.1.1 Adrenoleukodystrophy Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Adrenoleukodystrophy Drugs Production Mode & Process
- 8.2 Adrenoleukodystrophy Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Adrenoleukodystrophy Drugs Distributors
- 8.2.3 Adrenoleukodystrophy Drugs Customers
9 Global Adrenoleukodystrophy Drugs Analyzing Market Dynamics
- 9.1 Adrenoleukodystrophy Drugs Industry Trends
- 9.2 Adrenoleukodystrophy Drugs Industry Drivers
- 9.3 Adrenoleukodystrophy Drugs Industry Opportunities and Challenges
- 9.4 Adrenoleukodystrophy Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst